UCB SA UCB.BR

Located in Brussels, Belgium, UCB SA is a biopharmaceutical company that was founded in 1928. UCB's primary source of revenue is the design and development of pharmaceuticals for diseases such as epilepsy, Parkinson’s and Crohn’s. Some of the company’s more notable drugs on the market include Atarax, Cmzia, Vimpat, and Zyrtec. Kremers Urban Pharmaceuticals, the company’s American subsidiary was sold to Laennet Company in 2015 for $1.23 billion. UCB has operations in over 40 countries.

UCB went public in 1999 and is traded on the Euronext, the largest stock exchange in Europe, featuring companies from Amsterdam, Brussels, Dublin, Lisbon, London, Oslo and Paris. The Euronext was created in 2000 as the result of a merger between the Amsterdam, Brussels and Paris exchanges.

In 2019, UCB acquired Ra Pharma, a company specialising in immune system therapy, for $2.1 billion. Based in Boston, Ra Pharma was founded in 2008 and is listed on the Nasdaq exchange. The transaction was largely conducted in cash, with some financial assistance provided by the Bank of America and Merrill Lynch.

Find out what the eToro community thinks about UCB by visiting the stock’s page on the platform.